# Ledipasvir-Sofosbuvir

## Harvoni  90/400mg

| 藥物代碼 | OHARV |
| :--- | :--- |
| 適應症 | Treatment of chronic HCV genotype 1 infection in adults. |
| 副作用 | &gt;10%: Central nervous system: Headache \(11% to 29%\), fatigue \(10% to 18%\)Neuromuscular & skeletal: Weakness \(18% to 31%\)1% to 10%: Central nervous system: Irritability \(8%\), insomnia \(3% to 6%\), dizziness \(5%\), depression \(3 x ULN: ?9%\), diarrhea \(3% to 7%\)Hepatic: Hyperbilirubinemia \(&gt;1.5 x ULN: ?3%\) Neuromuscular & skeletal: Myalgia \(9%\), increased creatine phosphokinase \(1%\)Respiratory: Cough \(5%\), dyspnea \(3%\)&lt;1% \(Limited to important or life-threatening\): Skin rash \(with blisters or angioedema-like swelling\) |
| 禁忌 | If ledipasvir/sofosbuvir is administered with ribavirin, the contraindications to ribavirin also apply. Hypersensitivity to any component of the formulation. |
| 藥物保存方式 | N/A |
| 用法用量 | One tablet once daily with concomitant ribavirin for 12 weeks. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | 以上懷孕分級依據藥品仿單。 |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

